echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Dongyang Sunshine's "Entacapone Film" Approved for Listing

    Dongyang Sunshine's "Entacapone Film" Approved for Listing

    • Last Update: 2021-04-27
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, the official website of the State Food and Drug Administration showed that the entacapone tablets declared by Dongyang Sunshine according to registration classification 4 have been approved for marketing by NMPA (approval number: National Medicine Standard H20213207).


    Entacapone was developed by Orion Pharma and was first approved for marketing in Europe in 1998.


    Entacapone is a reversible and specific peripheral catechol O-methyltransferase (COMT) inhibitor, which reduces the metabolism of levodopa to 3-O-methyldopa (3-OMD) by inhibiting the COMT enzyme , Thereby increasing the bioavailability of levodopa, increasing the total amount of levodopa available in the brain, prolonging its clinical effect, and helping patients achieve motor symptom control.


    In November 2018, the entacapone film produced by Dongyang Sunshine was produced in the same production line according to the priority review scope (1).


    In addition to Dongyang Sunshine's approval of the product, Hainan General Kangli Pharmaceutical will also apply for production in February 2020 according to category 4 after completing the BE study.


    Fosun Pharma’s application for the same target drug Opicapone Capsules introduced from Ongentys was also accepted by the CDE on March 10.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.